Background: A novel chewable oral tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio ™) has recently been developed to provide persistent protection against flea and tick infections for a month, treatment of hookworm and roundworm infections and prevention of heartworm and lungworm disease in dogs. Two field studies were conducted to evaluate the safety and efficacy of Simparica Trio ™ against natural flea and tick infestations on dogs in Europe. Methods: Dogs with natural flea or tick infestations were allocated randomly to treatment on Day 0 with either Simparica Trio ™ tablets (flea study: n = 297; tick study: n = 189) to provide 1.2-2.4 mg/kg sarolaner, 24-48 µg/kg moxidectin and 5-10 mg/kg pyrantel (as pamoate salt) or with NexGard ® Spectra (afoxolaner + milbemycin oxime) according to the label instructions (flea study: n = 164; tick study: n = 91). Efficacy was calculated based on the mean percent reduction in live parasite counts compared to the respective pre-treatment counts on Days 14 and 30 in the flea study and on Days 7, 14, 21 and 30 in the tick study. To count the fleas, the dog's entire coat was systematically combed using an extra fine-tooth flea comb until all fleas were removed. For the tick counts, the dog's entire coat was searched manually. Resolution of the clinical signs of flea allergy dermatitis (FAD) was assessed in flea allergic dogs in the flea study. Palatability was assessed in both studies. Results: Simparica Trio ™ was well tolerated in both studies. Efficacy against fleas was ≥ 97.9% in the Simparica Trio ™ group and ≥ 96.1% in the NexGard ® Spectra group. Efficacy against ticks was ≥ 94.8% in the Simparica Trio ™ group and ≥ 94.4% in the NexGard ® Spectra group. Clinical signs of flea allergy dermatitis improved following treatment with Simparica Trio ™. Simparica Trio ™ tablets were voluntarily and fully consumed on ≥ 78% of the 485 occasions they were offered. Conclusions: A single oral dose of Simparica Trio ™ was safe and highly efficacious against naturally occurring flea and tick infestations for 1 month on dogs. Clinical signs of FAD improved following treatment. Simparica Trio ™ was voluntarily and readily consumed by most dogs.

Background: Gastrointestinal nematodes are parasites that commonly infect dogs, and infections can be subclinical or may cause considerable clinical disease. Some species are zoonotic and may also cause clinical disease in humans. Year-round treatment of dogs is recommended to eliminate existing infections, which also indirectly reduces the potential for subsequent human exposure to zoonotic species. Here we present two studies that evaluated the safety and efficacy of a novel chewable oral tablet containing sarolaner, moxidectin and pyrantel against gastrointestinal nematode infections in dogs presented as veterinary patients in Europe and the USA. Methods: Dogs naturally infected with Toxocara canis, Toxascaris leonina, Ancylostoma caninum and/or Uncinaria stenocephala were enrolled in the European study, and dogs naturally infected with T. canis were enrolled in the USA study. The animals were treated once orally with Simparica Trio ™ tablets to provide 1.2-2.4 mg/kg sarolaner, 24-48 µg/kg moxidectin and 5-10 mg/kg pyrantel (as pamoate salt) or with a commercially available product according to the label directions as positive control. Efficacy was based on the post-treatment reduction in geometric mean egg counts (per gram feces) 7 or 10 days after treatment compared to pre-treatment egg counts. Results: Simparica Trio ™ was well tolerated in both studies. In the European study, geometric mean egg counts for T. canis, T. leonina, A. caninum and U. stenocephala were reduced by ≥ 98.3% in the Simparica Trio ™ group and by ≥ 97.4% in the afoxolaner + milbemycin oxime group. In the USA study, geometric mean egg counts for T. canis were reduced by 99.2% in the Simparica Trio ™ group and by 98.6% in the ivermectin + pyrantel group. In the USA study, 48 and 10 dogs in the Simparica Trio ™ and the ivermectin + pyrantel group, respectively, were co-infected with A. caninum and the reduction in the post-treatment mean fecal egg counts were 98.6% and 74.7%, respectively.

Although shown here as a common diagnosis in pri mary-care practice, obesity is still not yet universally accepted as a disease, despite negative health and welfare consequences. This study suggests veterinarians should particularly emphasise obesity prevention and management in brachycephalic and neutered dogs, and that future obesity should be considered during neutering decision-making, especially in high-risk breeds.

The efficacy of a novel oral endectocide containing moxidectin, sarolaner and pyrantel was investigated in client-owned dogs with natural infections of Toxocara canis, Toxascaris leonina, Ancylostoma caninum and Uncinaria stenocephala. MethodsDogs infected with any of the four gastrointestinal nematode species were enrolled in this controlled, masked, randomized study. In total, 194 dogs were treated once orally with the combination of sarolaner (1.2 to 2.4 mg/kg), moxidectin (24 to 48 µg/kg) and pyrantel (5 to 10 mg/kg) and 97 dogs were treated with a positive control product containing afoxolaner (2.50-5.36 mg/kg) and milbemycin oxime (0.50-1.07 mg/kg). Faecal egg counts were conducted before, and 7 days after treatment administration. Efficacy was based on the post-treatment reduction in geometric mean egg counts (per gram faeces) compared to pre-treatment. ResultsTwo hundred dogs were infected with T. canis, 80 with A. caninum, 36 with U. stenocephala, and 16 with T. leonina. Fifty dogs had mixed infections with two or more species. Post-treatment geometric mean fecal egg counts for T. canis, A. caninum, T. leonina, and U. stenocephala relative to pretreatment counts were significantly (P<0.0001) reduced by ≥98.3% in the group treated with the combination of sarolaner, moxidectin and pyrantel, and by ≥ 97.4% in the afoxolaner and milbemycin oxime-treated group. Both products were well tolerated. Statement (conclusions)Oral administration of the combination of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5.0 mg/kg pyrantel provided effective treatment of roundworm and hookworm infection in dogs.